Valion Bio raises $7.737 million via Series B/C preferred and warrants
Valion Bio entered a private placement letter agreement with 3i to issue Series B and Series C preferred shares with accompanying warrants for $7.737 million.
Valion Bio entered into a private placement Letter Agreement with 3i to issue Series B and Series C preferred shares and accompanying warrants for $7.737 million.
Of the purchase price, $6.137 million will satisfy overdue true-up payments and $100,000 will cover 3i’s legal fees, with $1.5 million p…